ConductScience.org, home

Comparison · NCT00809055-167f0970

High Dose Caffeine vs Standard Dose Caffeine: Rates of Chronic Lung Disease

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. High Dose Caffeine vs Standard Dose Caffeine: Rates of Chronic Lung Disease. Trial comparisons, record NCT00809055-167f0970. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00809055-167f0970

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5140.3590.666wilson
Risk in group 20.4860.3340.641wilson
Risk difference, group 1 minus group 20.027-0.1920.242newcombe hybrid score
Risk ratio, group 1 over group 21.060.6691.67log
Odds ratio, group 1 over group 21.110.4482.77log
Number needed to treat, for one more participant with the outcome on High Dose Caffeine than on Standard Dose Caffeine37from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1High Dose Caffeine
Loading dose 40mg/kg IV caffeine citrate, followed 12 hours later by 20mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate.~Caffeine citrate: Caffeine to be administered as outlined to compare efficacy of different dosages.
1937OG000
Group 2Standard Dose Caffeine
Loading dose 20mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo, followed 12 hours later with 10mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo.~Caffeine citrate: Caffeine to be administered as outlined to compare efficacy of different dosages.
1837OG001

Outcome

Type
SECONDARY
Title
Rates of Chronic Lung Disease
Description
Defined as oxygen requirement at 36 weeks PMA
Time frame
Participants were followed for the duration of hospital stay, an average of 12 weeks
Population

Source ClinicalTrials.gov

Trial

Title
MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine
NCT number
NCT00809055
Phases
PHASE4
Conditions
Apnea of Prematurity, Intraventricular Hemorrhage, Brain Injury
Interventions
Caffeine citrate
Lead sponsor
Washington University School of Medicine
Results first posted
2016-02-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00809055-167f0970